(4R,5R,6S,Z)-4,5-bis((tert-butyldimethylsilyl)oxy)-6-methoxy-2-methylocta-2,7-dien-1-yl hept-6-enoate | 1253795-91-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (4R,5R,6S,Z)-4,5-bis((tert-butyldimethylsilyl)oxy)-6-methoxy-2-methylocta-2,7-dien-1-yl hept-6-enoate
• CAS: 1253795-91-3
• 化学式: C₂₉H₅₆O₅Si₂
• 分子量: 540.932
• InChiKey: SQIIPMREUYJGCB-NAVYXTIISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  36.0
• 可旋转键数：
  16.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  53.99
• 氢给体数：
  0.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  (4R,5R,6S,Z)-4,5-bis((tert-butyldimethylsilyl)oxy)-6-methoxy-2-methylocta-2,7-dien-1-yl hept-6-enoate 在 Grubbs-II 作用下， 以 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Synthesis of congeners of migrastatin and dorrigocin A from d-xylose

  摘要：

  Migrastatin and dorrigocin A analogues have potential as anti-metastatic agents that act by targeting the actin-bundling protein, fascin. Syntheses of close structural analogues of these agents have been achieved. Wittig and Ando olefination reactions with an aldehyde obtained from D-xylose, respectively, gave two trisubstituted alkene intermediates that were then elaborated into either macrolactone or macrolactam analogues of migrastatin or to an acyclic dorrigocin A analogue. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.07.141
• 作为产物：
  描述：

  6-庚烯酸 、 (2Z,4R,5R,6S)-4,5-bis[[tert-butyl(dimethyl)silyl]oxy]-6-methoxy-2-methylocta-2,7-dien-1-ol 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 甲苯 为溶剂， 以85%的产率得到(4R,5R,6S,Z)-4,5-bis((tert-butyldimethylsilyl)oxy)-6-methoxy-2-methylocta-2,7-dien-1-yl hept-6-enoate
  参考文献：
  名称：

  Synthesis of congeners of migrastatin and dorrigocin A from d-xylose

  摘要：

  Migrastatin and dorrigocin A analogues have potential as anti-metastatic agents that act by targeting the actin-bundling protein, fascin. Syntheses of close structural analogues of these agents have been achieved. Wittig and Ando olefination reactions with an aldehyde obtained from D-xylose, respectively, gave two trisubstituted alkene intermediates that were then elaborated into either macrolactone or macrolactam analogues of migrastatin or to an acyclic dorrigocin A analogue. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.07.141